Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evolution of clinical features in possible DLB depending on FP-CIT SPECT result.
Walker Z, Moreno E, Thomas A, Inglis F, Tabet N, Stevens T, Whitfield T, Aarsland D, Rainer M, Padovani A; DaTSCAN DLB Phase 4 Study Group. Walker Z, et al. Among authors: inglis f. Neurology. 2016 Sep 6;87(10):1045-51. doi: 10.1212/WNL.0000000000003076. Epub 2016 Aug 10. Neurology. 2016. PMID: 27511183 Free PMC article. Clinical Trial.
Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.
Wolk DA, Sadowsky C, Safirstein B, Rinne JO, Duara R, Perry R, Agronin M, Gamez J, Shi J, Ivanoiu A, Minthon L, Walker Z, Hasselbalch S, Holmes C, Sabbagh M, Albert M, Fleisher A, Loughlin P, Triau E, Frey K, Høgh P, Bozoki A, Bullock R, Salmon E, Farrar G, Buckley CJ, Zanette M, Sherwin PF, Cherubini A, Inglis F. Wolk DA, et al. Among authors: inglis f. JAMA Neurol. 2018 Sep 1;75(9):1114-1123. doi: 10.1001/jamaneurol.2018.0894. JAMA Neurol. 2018. PMID: 29799984 Free PMC article.
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
Burns DK, Alexander RC, Welsh-Bohmer KA, Culp M, Chiang C, O'Neil J, Evans RM, Harrigan P, Plassman BL, Burke JR, Wu J, Lutz MW, Haneline S, Schwarz AJ, Schneider LS, Yaffe K, Saunders AM, Ratti E; TOMMORROW study investigators. Burns DK, et al. Lancet Neurol. 2021 Jul;20(7):537-547. doi: 10.1016/S1474-4422(21)00043-0. Lancet Neurol. 2021. PMID: 34146512 Clinical Trial.
Open and reusable deep learning for pathology with WSInfer and QuPath.
Kaczmarzyk JR, O'Callaghan A, Inglis F, Gat S, Kurc T, Gupta R, Bremer E, Bankhead P, Saltz JH. Kaczmarzyk JR, et al. Among authors: inglis f. NPJ Precis Oncol. 2024 Jan 10;8(1):9. doi: 10.1038/s41698-024-00499-9. NPJ Precis Oncol. 2024. PMID: 38200147 Free PMC article.
71 results